A trial of TDM1 after surgery for breast cancer (KATHERINE)

This trial looked at trastuzumab emtansine (TDM1) to reduce the risk of breast cancer coming back or spreading elsewhere in the body.

It was for people:

• who’d had treatment to shrink their cancer before surgery but had some cancer remaining

• whose cancer was HER2 positive

The trial was open for people to join between 2013 and 2015. The team published some early results in 2019. They presented longer term results at a conference in December 2023.